Search

Byline: Krati. Srivastava, Kavita. Bhatnagar, Jyoti. Shakrawal, Manjari. Tandon, Kirti. Jaisingh, Latika. Pandey, Falguni. Roy Purpose: To examine the ocular surface disease in primary open-angle glaucoma (POAG) patients already on [...]

The Food and Drug Administration (FDA) has approved Omlonti[sup.®] (omidenepag isopropyl ophthalmic solution) 0.002% for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular [...]

2022 FEB 12 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Drugs and Therapies - Ophthalmic Glaucoma Agents. [...]

Byline: Sherein. Hagras, Omar. Al-Duwailah, Mona. Nassief, Ameera. Abdelhameed Purpose: To compare the efficacy and the tolerability of preservative-free Tafluprost 0.0015% (TP) vs Latanoprost 0.005% (LP) in patients with primary [...]

With primary open-angle glaucoma (POAG) being one of the leading causes of blindness worldwide, there is continual effort to explore and develop new modalities to treat this condition. (1) Although [...]

2019 MAR 9 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Staff editors report on the newly launched clinical trial, NCT03844945, which has [...]

Objective: To investigate the prevalence of 'masked' pseudoexfoliation (PEX) syndrome in eyes with circular posterior synechiae receiving antiglaucomatous therapy with miotics. Design: Cross-sectional prospective study. Methods: Twenty-eight eyes of 27 consecutive patients with circular posterior synechiae and a history of miotic drug use without previous intraocular surgery, inflammation, or trauma, and without conventional signs of PEX material in the anterior chamber were included in the study. All eyes were investigated by slitlamp biomicroscopy and gonioscopy of the anterior chamber before extracapsular cataract surgery for the presence of typical PEX-associated iris pigment epithelial changes, such as peripupillary atrophy and trabecular meshwork melanin granule deposition. The anterior chamber depth, lens thickness, and axial lengths of the eyes were measured by A-scan immersion sonography. The excised anterior lens capsules obtained during extracapsular cataract surgery were investigated for the presence of precapsular fibrillar PEX deposits by electron microscopy. Main Outcome Measure: The prevalence of masked PEX syndrome in eyes with circular posterior synechiae receiving antiglaucomatous therapy with miotics. Results: Transmission electron microscopy of unselected nonserial sections revealed a precapsular layer consisting of typical PEX fibers or microfibrils, which indicated early stages of PEX syndrome in 18 (64%) of 28 eyes with circular posterior synechiae. Melanin granules were frequently found adhering to the fibrillar layer. Eyes with precapsular fibrillar deposits showed significantly greater trabecular meshwork pigmentation than eyes without such deposits. Differences in age, lens thickness, axial length of the eye, anterior chamber depth, and degree of peripupillary atrophy were, however, not statistically significant between the groups with and without electron microscopic evidence of PEX deposits. Conclusions: Circular posterior synechiae were more frequently associated with manifest or early stages of PEX syndrome. However, the formation of broad posterior synechiae in miosis prevented a definite clinical diagnosis based on the classic changes of the anterior lens capsule. In eyes with spontaneous or miotic-induced circular posterior synechiae without other obvious cause, the masked variant of PEX syndrome should always be considered. Arch Ophthalmol. 2001;119:1500-1504

Primary open-angle glaucoma is a condition associated with an elevated intraocular pressure (IOP) that is defined as optic nerve degeneration with a slowly progressive deterioration of the visual field that may lead to blindness.[1] More than I million Americans are being treated for glaucoma, and 80 000 are legally blind as a result of the disease.[2] Glaucoma has its highest prevalence among the elderly population, with an incidence of approximately 1% in those older than 60 years, 3% in those between the ages of 70 and 80 years, and more than 9% in those older than 80 years.[3] Treatment is directed at lowering high ocular pressures. The initial treatment, in most cases topical therapy with a [Beta]-adrenergic blocking agent, reduces the IOP to help preserve sight. But such topical agents may also have adverse systemic effects on cardiac, pulmonary, central nervous system (CNS), and endocrine functions.

2015 NOV 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Eye Diseases and Conditions is now available. According [...]

Glaucoma, an abnormal condition of elevated pressure within the eye caused by obstruction of the outflow of aqueous humor from the anterior portion of the eye between the cornea and the lens, is frequently treated with local application (in the form of eye drops) of beta-blockers. Two areas of concern with this treatment are the possibility of body-wide side effects from this medication and lack of patient compliance. The usual medical regimen involves twice daily instillation of the eyedrops. The maximum dosage schedule is twice a day instillation of 0.5 percent strength medication. It would be desirable if the frequency and strength of the dose could be reduced. Once-daily administration might result in better patient compliance. A three-month study was undertaken of patients with open-angle glaucoma to evaluate a once-daily regimen of 0.25 percent of levobunolol or timolol. Prior to beginning the study, intraocular pressure, heart rate and blood pressure were measured. There were 37 patients in the levobunolol group and 41 in the timolol group. The overall decrease in intraocular pressure was 5.3 mm Hg in the levobunolol group and 5.4 mm in the timolol - not a statistically significant difference. At the end of the study there were no significant differences in either blood pressure or heart rate. These findings suggest that once-daily administration of 0.25 percent levobunolol or timolol are equally effective in controlling intraocular pressure. Compared with other studies, the percent reduction in pressure obtained was similar to that observed with once-daily administration of 5 percent levobunolol or twice daily administration of 0.25 percent medication. (Consumer Summary produced by Reliance Medical Information, Inc.)

Allergan has launched Combigan, an eye drop preparation containing brimonidine tartrate 2mg and timolol 5mg per ml. The black triangle product is indicated for the reduction of intraocular pressure in [...]

Reviewed by Gregory L. Skuta, MD, and Henry D. Jampel, MD, MHS Not long after topical timolol was introduced in 1978, it became one of the most widely prescribed glaucoma [...]

(Travoprost, Alcon Laboratories) Travatan is a prostaglandin analogue indicated for the reduction of intraocular hypertension or open-angle glaucoma in patients who are intolerant or insufficiently responsive to other treatments. It [...]

Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) Class: [Alpha.sub.2] agonist Manufacturer: Allergan, Inc Indication: Treatment of elevated IOP in patients who have open-angle glaucoma or ocular hypertension Common adverse effects: [...]

Class: Prostaglandin analog Manufacturer: Alcon Universal, Ltd Indication: Treatment of elevated IOP in open-angle glaucoma or ocular hypertension in patients who are intolerant of or who have not responded to [...]

Bimatoprost ophthalmic solution 0.03% Allergan Travatan Travoprost ophthalmic solution 0.004% Alcon Prostaglandin analogs for open-angle glaucoma, ocular hypertension The FDA has separately approved two new ophthalmic solution products--bimatoprost and travoprost--for [...]